[Evolution of endocrine therapy for prostate cancer].
作者信息
Igawa T, Saito Y
机构信息
Department of Urology, Nagasaki University School of Medicine.
出版信息
Nihon Rinsho. 2000 Jul;58 Suppl:176-81.
PMID:11022709
Abstract
摘要
相似文献
1
[Evolution of endocrine therapy for prostate cancer].[前列腺癌内分泌治疗的进展]
Nihon Rinsho. 2000 Jul;58 Suppl:176-81.
2
Choice of first-line treatment for metastatic prostate cancer.转移性前列腺癌一线治疗的选择。
Prescrire Int. 2013 Feb;22(135):51.
3
Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.亮丙瑞林、曲普瑞林：新适应症。局部晚期前列腺癌：最低限度评估的仿制药。
Prescrire Int. 2007 Dec;16(92):243.
4
Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.醋酸亮丙瑞林和醋酸戈舍瑞林在抑制前列腺癌患者血清睾酮水平方面具有等效且充分的效果。
BJU Int. 2008 May;101(9):1096-100. doi: 10.1111/j.1464-410X.2007.07374.x. Epub 2008 Jan 8.
5
Secondary hormonal therapy.二线激素治疗
Semin Urol Oncol. 1997 Feb;15(1):3-12.
6
[Total androgen blockade].[全雄激素阻断]
Nihon Rinsho. 2002 Dec;60 Suppl 11:193-8.
7
Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.前列腺癌男性患者的雄激素剥夺与骨丢失率增加有关。
Prostate Cancer Prostatic Dis. 2002;5(4):304-10. doi: 10.1038/sj.pcan.4500599.
8
[Endocrine therapy for prostate cancer in the future].[未来前列腺癌的内分泌治疗]
Gan To Kagaku Ryoho. 1998 May;25(6):817-22.
9
Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.前列腺癌根治术及术前有无雄激素剥夺的辅助内分泌治疗：五年结果
Int J Urol. 2004 May;11(5):295-303. doi: 10.1111/j.1442-2042.2004.00795.x.
10
Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.近距离放射治疗前单独使用比卡鲁胺可实现细胞减灭，这与促黄体生成素释放激素类似物相似，但患者报告的发病率较低。
Urol Oncol. 2008 Jul-Aug;26(4):372-7. doi: 10.1016/j.urolonc.2007.05.014. Epub 2008 Jan 8.
Zotero 插件